Yi Shou
Overview
Explore the profile of Yi Shou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Chen K, Shou Y, Li S, Wang J, Zhang Q, et al.
Clin Transl Med
. 2023 Dec;
13(12):e1512.
PMID: 38073586
As the most prominent RNA modification, N6-methyladenosine (m A) participates in the regulation of tumour initiation and progression. Circular RNAs (circRNAs) also play crucial roles in ubiquitous life processes. Whether...
2.
Shou Y, Yue C, Wang Q, Liu J, Xu J, Miao Q, et al.
Cell Death Dis
. 2023 Mar;
14(3):232.
PMID: 37002206
Renal cell carcinoma (RCC) is characterized by the difficulties in early diagnosis and the propensity to metastases. For advanced RCC, sunitinib targeted therapy is the clinically recommended first-line drug and...
3.
Wang Q, Gao S, Shou Y, Jia Y, Wei Z, Liu Y, et al.
Int J Biol Sci
. 2023 Mar;
19(4):1266-1283.
PMID: 36923928
Renal cell carcinoma (RCC) is a serious threat to people's health due to its rapid progression, and patients easily develop resistance to targeted therapy. The absent in melanoma 2 (AIM2)...
4.
Liu Y, Wang J, Shou Y, Xu W, Huang Z, Xu J, et al.
Cell Death Dis
. 2022 Jul;
13(7):578.
PMID: 35787628
Abnormal accumulation of lipids has been highlighted in the progression of clear cell renal cell carcinoma (ccRCC). However, the underlying mechanism remains unclear. Emerging evidence suggests long noncoding RNAs (lncRNAs)...
5.
Shou Y, Liu Y, Xu J, Liu J, Xu T, Tong J, et al.
Front Genet
. 2022 Mar;
13:648134.
PMID: 35281807
Renal cell carcinoma (RCC) is one of the most common malignancies in the urinary system. The mortality of advanced RCC remains high despite advances in systemic therapy of RCC. Considering...
6.
Wang Q, Xu J, Xiong Z, Xu T, Liu J, Liu Y, et al.
J Transl Med
. 2021 Oct;
19(1):417.
PMID: 34627268
Clear cell renal cell carcinoma (ccRCC) is the most common malignant tumor of the kidney. New and reliable biomarkers are in urgent need for ccRCC diagnosis and prognosis. The CENP...
7.
Xu J, Liu Y, Liu J, Shou Y, Xiong Z, Xiong H, et al.
Front Oncol
. 2021 Jul;
11:659208.
PMID: 34249694
Clear cell renal cell carcinoma (ccRCC) accounts for approximately 4/5 of all kidney cancers. Accumulation of minor changes in the cellular homeostasis may be one cause of ccRCC. Therefore, we...
8.
Shou Y, Xue Q, Yuan J, Zhao J
Eur J Hybrid Imaging
. 2021 Jun;
5(1):12.
PMID: 34181149
Introduction: Ga-fibroblast activation protein-specific enzyme inhibitor 04 (FAPI-04) is a radiolabelled molecular agent targeting the inhibitor of fibroblast activation protein (FAP), which is often present in tumor stroma and inflammatory...
9.
Liu Y, Huang Z, Cheng G, Shou Y, Xu J, Liu D, et al.
Genomics
. 2021 Apr;
113(4):1816-1827.
PMID: 33838279
This study aimed to develop a prognostic model for clear cell renal cell carcinoma (ccRCC) based on transcriptome analysis. We screened Gene Expression Omnibus (GEO) database and the Cancer Genome...
10.
Qi N, Meng Q, You Z, Chen H, Shou Y, Zhao J
BMC Med Imaging
. 2021 Feb;
21(1):39.
PMID: 33639883
Background: Quantitative bone SPECT/CT is useful for disease follow up and inter-patient comparison. For bone metastatic malignant lesions, spine is the most commonly invaded site. However, Quantitative studies with large...